- Home
- SITC vs DAWN Comparison
SITC vs DAWN Comparison
Compare SITC & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- DAWN
- Stock Information
- Founded
- SITC 1965
- DAWN 2018
- Country
- SITC United States
- DAWN United States
- Employees
- SITC N/A
- DAWN N/A
- Industry
- SITC Real Estate Investment Trusts
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- DAWN Health Care
- Exchange
- SITC Nasdaq
- DAWN Nasdaq
- Market Cap
- SITC 600.0M
- DAWN 658.9M
- IPO Year
- SITC 1993
- DAWN 2021
- Fundamental
- Price
- SITC $10.63
- DAWN $6.65
- Analyst Decision
- SITC Hold
- DAWN Strong Buy
- Analyst Count
- SITC 8
- DAWN 6
- Target Price
- SITC $35.25
- DAWN $30.17
- AVG Volume (30 Days)
- SITC 1.1M
- DAWN 1.3M
- Earning Date
- SITC 08-05-2025
- DAWN 08-05-2025
- Dividend Yield
- SITC 14.18%
- DAWN N/A
- EPS Growth
- SITC 151.17
- DAWN N/A
- EPS
- SITC 10.32
- DAWN N/A
- Revenue
- SITC $227,525,000.00
- DAWN $161,922,000.00
- Revenue This Year
- SITC N/A
- DAWN $16.42
- Revenue Next Year
- SITC $5.90
- DAWN $47.52
- P/E Ratio
- SITC $1.04
- DAWN N/A
- Revenue Growth
- SITC N/A
- DAWN N/A
- 52 Week Low
- SITC $10.46
- DAWN $6.08
- 52 Week High
- SITC $18.15
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- SITC 35.41
- DAWN 46.52
- Support Level
- SITC $10.75
- DAWN $6.32
- Resistance Level
- SITC $11.43
- DAWN $7.18
- Average True Range (ATR)
- SITC 0.29
- DAWN 0.29
- MACD
- SITC -0.02
- DAWN -0.01
- Stochastic Oscillator
- SITC 12.94
- DAWN 30.56
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.